Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
antibiotic-resistant bacteria
Biotech
GSK drops celiac disease program acquired in Sitari buyout
Four years after buying Sitari, GSK has dropped plans to develop its candidate in celiac disease while leaving the door open to other indications.
Nick Paul Taylor
Feb 1, 2023 6:40am
'Uninterpretable' phase 3 results stymie ContraFect
Dec 20, 2022 1:18pm
ContraFect halts phase 3 after antimicrobial fails futility test
Jul 14, 2022 10:35am
Stopping DNA 'packet' exchange could halt bacterial resistance
Jun 14, 2022 8:30am
Lack of policy, investment stifling antibiotics pipeline
Apr 12, 2022 9:00am
Big Pharma-backed AMR Action Fund picks 1st biotech investments
Apr 4, 2022 10:25am
